Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 8Thoracic 3Lymphoid 2Gynecologic 2Gastrointestinal 2Dermatologic 2Genitourinary 1CNS 1Breast 1

Conditions

Melanoma 4Colorectal Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Microsatellite Instability 1Mesothelioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Merkel Cell 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 29Cetuximab 11Nivolumab 10Fluorouracil 8Cyclophosphamide 8Cisplatin 8Carboplatin 8fludarabine 7atezolizumab 7Blood Specimen Collection 7cemiplimab 6Radiotherapy 6Drug Therapy 6Immune Checkpoint Inhibitors 5Gemcitabine 5Paclitaxel 4Docetaxel 4Capecitabine 4Biopsy 4spartalizumab 3avelumab 3Surveys and Questionnaires 3Pemetrexed 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Ipilimumab 3Interleukin-2 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × epacadostat × Gastrointestinal × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡